Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 9, 2024 5:00 PM EDTIRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an... More
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 8, 2024 4:05 PM EDTGenerated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients
Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025
Expanded sales force on-track to be in the field by the end of the third quarter 2024
Strengthened financial position with an approximately $108 million public equity offering and $200 million financing commitment
... More